Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUWIN phase II study of durvalumab and tremelimumab with Y-90 SIRT or DEB-TACE in intermediate-stage hepatocellular carcinoma
2019-004597-26Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Started Apr 2020; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-004597-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004597-26.